journal
Journals Drug Metabolism and Pharmacoki...

Drug Metabolism and Pharmacokinetics

https://read.qxmd.com/read/38547661/population-pharmacokinetics-of-everolimus-in-renal-transplant-recipients-receiving-long-term-multiple-immunosuppressive-therapy
#1
JOURNAL ARTICLE
Tomoyuki Sakaue, Kazuhiro Yamamoto, Kotaro Itohara, Yumi Kitahiro, Takahito Endo, Naoki Yokoyama, Takeshi Ishimura, Tomohiro Omura, Ikuko Yano
Everolimus is used for immunosuppression after renal transplantation. This study aimed to develop a population pharmacokinetic (PopPK) model of everolimus using therapeutic drug monitoring (TDM) data of patients under long-term multiple immunosuppressive therapy, including tacrolimus. To develop the model, 185 renal transplant recipients with 3358 everolimus blood concentrations during a median postoperative period of 35.3 months were included. The PopPK model is described as a one-compartment model with first-order absorption...
March 12, 2024: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38452615/transcript-abundance-of-hepatic-drug-metabolizing-enzymes-in-two-dog-breeds-compared-with-14-species-including-humans
#2
JOURNAL ARTICLE
Yasuhiro Uno, Osamu Yamato, Hiroshi Yamazaki
Drug-metabolizing enzymes are important in drug development and therapy, but have not been fully identified and characterized in many species, lines, and breeds. Liver transcriptomic data were analyzed for phase I cytochromes P450, flavin-containing monooxygenases, and carboxylesterases and phase II UDP-glucuronosyltransferases, sulfotransferases, and glutathione S-transferases. Comparisons with a variety of species (humans, rhesus macaques, African green monkeys, baboons, common marmosets, cattle, sheep, pigs, cats, dogs, rabbits, tree shrews, rats, mice, and chickens) revealed both general similarities and differences in the transcript abundances of drug-metabolizing enzymes...
January 26, 2024: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38643548/unveiling-the-intra-tumor-fate-of-trastuzumab-deruxtecan-in-a-xenograft-model-to-support-its-mechanism-of-action
#3
JOURNAL ARTICLE
Yoko Nagai, Masataka Oitate, Takahiro Shibayama, Hideo Takakusa, Nobuaki Watanabe
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate used for cancer treatment comprising an anti-human epidermal growth factor receptor type 2 (HER2) antibody and the topoisomerase I inhibitor DXd. The present study investigated the intratumor fate of T-DXd. Fluorescence-labeled T-DXd was found to accumulate in tumors of HER2-positive tumor xenograft mice and was observed to be distributed within lysosomes of in vitro tumor cells in accordance with their HER2 expression. DXd was released by cysteine proteases, including cathepsins, in lysosomal fractions in vitro in response to the pH...
January 23, 2024: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38458122/physiologically-based-pharmacokinetic-modeling-to-predict-the-clinical-effect-of-azole-antifungal-agents-as-cyp3a-inhibitors-on-azelnidipine-pharmacokinetics
#4
JOURNAL ARTICLE
Akiko Watanabe, Masakatsu Kotsuma
In this study, a physiologically based pharmacokinetic (PBPK) model of the cytochrome P450 3A (CYP3A) substrate azelnidipine was developed using in vitro and clinical data to predict the effects of azole antifungals on azelnidipine pharmacokinetics. Modeling and simulations were conducted using the Simcyp™ PBPK simulator. The azelnidipine model consisted of a full PBPK model and a first-order absorption model. CYP3A was assumed as the only azelnidipine elimination route, and CYP3A clearance was optimized using the pharmacokinetic profile of single-dose 5-mg azelnidipine in healthy participants...
January 23, 2024: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38583388/predicting-muscarinic-receptor-occupancy-in-human-bladder-mucosa-from-urinary-concentrations-of-antimuscarinic-agents-for-overactive-bladder
#5
JOURNAL ARTICLE
Mizuki Shiho, Gaku Akashita, Eriko Nakatani, Shimako Tanaka, Shizuo Yamada, Takashi Okura
To assess the pharmacologically relevant and selective muscarinic receptor occupancy in the bladder mucosa, we considered not only plasma drug concentrations but also urinary drug concentrations. The purpose of this study was to predict muscarinic receptor occupancy in the human bladder mucosa based on urinary concentrations in response to clinical dosages of antimuscarinic agents used to treat overactive bladder. The calculated mean plasma or serum unbound steady state concentrations were 0.06-11 nM in clinical dosages of five antimuscarinic agents...
January 15, 2024: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38367298/preferential-meropenem-absorption-activated-by-1%C3%AE-25-dihydroxyvitamin-d-3-and-shared-with-foscarnet-a-phosphate-transporter-substrate-in-the-rat-ileum
#6
JOURNAL ARTICLE
Toshihide Saito, Yuichi Ichimura, Masako Oda, Hiroshi Saitoh
Meropenem (MEPM) is used for the treatment of serious infectious diseases solely as. INJECTABLE: Therefore, the development of an oral formulation would expand its clinical utility. To this end, an exact understanding of the absorption characteristics of MEPM is essential. In this study, MEPM absorption in the rat small intestine was investigated using an in situ loop technique and an in vitro diffusion chamber method. The disappearance ratios of MEPM (0.1 mM) were in the order of ileum > duodenum > jejunum...
January 11, 2024: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38447327/sodium-citrate-buffer-improves-pazopanib-solubility-and-absorption-in-gastric-acid-suppressed-rat-model
#7
JOURNAL ARTICLE
Huda Jassim Muhammad, Tsutomu Shimada, Arimi Fujita, Yoshimichi Sai
Pazopanib exhibits pH-dependent solubility and its absorption depends primarily on the stomach pH. Significant decrease of pazopanib absorption by coadministration with proton pump inhibitors in clinical situation need to be overcome. Thus, the purpose of this study is firstly to investigate the effect of acidic beverages and sodium citrate buffer on the solubility of pazopanib and secondly to examine the effect of sodium citrate buffer on pazopanib absorption in a rat model with esomeprazole-mediated gastric acid suppression...
January 3, 2024: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38452616/air-liquid-interface-culture-and-modified-culture-medium-promote-the-differentiation-of-human-induced-pluripotent-stem-cells-into-intestinal-epithelial-cells
#8
JOURNAL ARTICLE
Kotaro Shirai, Shimeng Qiu, Hanako Minowa, Tadahiro Hashita, Takahiro Iwao, Tamihide Matsunaga
An in vitro system that evaluates pharmacokinetics in the small intestine is crucial for the development of oral drugs. We produced human induced pluripotent stem cell-derived small intestinal epithelial cells (hiSIECs) with high drug metabolizing enzyme and drug transporter activities. However, the gene expression of our hiSIECs partially differed from that of the human small intestine, with low drug metabolizing enzyme activities. Therefore, we used air-liquid interface (ALI) culture and 5-aza-2'-deoxycytidine (5AZA)-free medium to generate hiSIECs (novel hiSIECs)...
December 31, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38280279/rare-but-impaired-flavin-containing-monooxygenase-3-fmo3-variants-reported-in-a-recently-updated-japanese-mega-databank-of-genome-resources
#9
JOURNAL ARTICLE
Makiko Shimizu, Miaki Makiguchi, Eiji Hishinuma, Sakae Saito, Masahiro Hiratsuka, Hiroshi Yamazaki
Genetic variants of human flavin-containing monooxygenase 3 (FMO3) were investigated using an updated Japanese population panel containing 54,000 subjects (the previous panel contained 38,000 subjects). One stop codon mutation and six amino acid-substituted FMO3 variants were newly identified in the updated databank. Of these, two substituted variants (p.Thr329Ala and p.Arg492Trp) were previously identified in compound haplotypes with p.[(Glu158Lys; Glu308Gly)] and were associated with the metabolic disorder trimethylaminuria...
December 22, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38150944/quantification-of-fluticasone-propionate-in-human-plasma-by-lc-ms-ms-and-its-application-in-the-pharmacokinetic-study-of-nasal-spray-at-clinical-doses
#10
JOURNAL ARTICLE
Aya Yamagata, Rena Adachi, Akitomo Yokokawa, Tomomi Furihata, Hiromi Shibasaki
We developed a method for quantifying fluticasone propionate (FP) using general-purpose liquid chromatography-tandem mass spectrometry equipment to measure the plasma concentration of FP for the pharmacokinetic study of FP following the administration of a prescribed nasal spray dose (100 μg). Using ammonium acetate (0.01 M)-formic acid (pH 2.9; 499:1, v/v) and methanol as the mobile phase, 3 pg/mL of FP was quantified. The relative error and standard deviation of the lower limit of quantification were <3...
December 11, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38029470/physiologically-based-pharmacokinetic-pbpk-model-that-describes-enhanced-fcrn-dependent-distribution-of-monoclonal-antibodies-mabs-by-pi-engineering-in-mice
#11
JOURNAL ARTICLE
Sotaro Naoi, Mizuki Yamane, Takayuki Nemoto, Motohiro Kato, Ryoichi Saito, Tatsuhiko Tachibana
We previously reported that monoclonal antibodies (mAbs) with a high isoelectric point (pI) value tended to exhibit fast plasma clearance (CL) and large steady-state volume of distribution (Vdss) in mice. However, the positive correlation between pI, CL, and Vdss cannot be described by the reported physiologically based pharmacokinetic (PBPK) models, in which FcRn-mediated transcytosis of mAbs is set to be minimal compared to convection-mediated transport. To address this issue, physiological parameters (lymph flow rate, reflection coefficient, endothelial uptake clearance, and FcRn concentration) were optimized based on the pharmacokinetic profiles of mAbs with various pI values in wild type and FcRn-deficient (beta-2-microglobulin knockout [KO]) mice...
December 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38244327/cross-species-drug-metabolism-and-impact-of-metabolic-stability-testing-under-anaerobic-condition-on-predicting-pharmacokinetics-of-keto-enol-containing-compound-in-humans
#12
JOURNAL ARTICLE
Takushi Kanazu, Junto Tamada, Susumu Kume, Tohru Mizutare
After oral administration of [14 C]-S-1360 in rats and dogs, [14 C]-S-1360 was absorbed rapidly and the bioavailability was 93.7% in rats and 75.1% in dogs. Based on the results in animals, good systemic exposure would be expected in humans. In contrast to the expectation, the exposure was low in healthy volunteers compared to the exposure expected. In addition, human mass balance study using [14 C]-S1360 revealed that a large amount of metabolites existed in human plasma. The major metabolites in human plasma were reduced metabolite (HP1) and S-1360 N-glucuronide, and they respectively accounted for approximately 30% of total AUC...
November 21, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38086197/physiologically-based-pharmacokinetic-model-analysis-of-the-inhibitory-effect-of-vonoprazan-on-the-metabolic-activation-of-proguanil
#13
JOURNAL ARTICLE
Kenjiro Okubo, Toshiyuki Kudo, Sae Yoshihara, Yu Nakabayashi, Kana Nakauchi, Akimi Tanaka, Moe Saito, Ayumi Tsujisawa, Hitomi Goda, Yoshiaki Yamagishi, Chinatsu Otake, Kosho Makino, Hideyo Takahashi, Kiyomi Ito
We previously reported that repeated oral administration of vonoprazan (VPZ) followed by oral administration of proguanil (PG) in healthy adults increased blood concentration of PG and decreased blood concentration of its metabolite cycloguanil (CG) compared with administration of PG alone. In this study, we investigated whether this interaction can be quantitatively explained by VPZ inhibition of PG metabolism. In an in vitro study using human liver microsomes, VPZ inhibited CG formation from PG in a concentration-dependent manner, and the inhibition was enhanced depending on preincubation time...
November 7, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38081105/improvement-of-transdermal-absorption-rate-by-nonthermal-biocompatible-atmospheric-pressure-plasma
#14
JOURNAL ARTICLE
Byoung-Choul Kim, Juie Nahushkumar Rana, Eun Ha Choi, Ihn Han
Nonthermal biocompatible plasma (NBP) is a promising option for improving medication absorption into the human skin. Currently, most plasma devices for cosmetics employ a floating-electrode plasma source for treating the skin. Human skin serves as the ground electrode in the floating-electrode plasma discharge, and discharge occurs between the skin and electrodes of the device. In this in vitro study, we aimed to evaluate the effect of NBP on the skin permeation of niacinamide. We have quantified the transdermal absorption rates of niacinamide in both untreated skin and skin treated with NBP for a duration of 10 s...
October 31, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38070310/construction-of-a-fused-grid-based-cyp2c18-template-system-and-its-application-to-drug-metabolism
#15
JOURNAL ARTICLE
Yasushi Yamazoe, Kouichi Yoshinari
Detailed estimation of cytochrome P450 (CYP)-mediated metabolisms of medicine and other chemicals is necessary for the efficacy and safety assessments. Data on the metabolisms mediated by minor CYP enzymes like CYP2C18 are often not available in metabolisms and safety assessments of chemicals except for medical drugs developed recently. A ligand-accessible space in the active site of human CYP2C18 was thus reconstituted as a fused grid-based Template with the use of structural data of its ligands. An evaluation system of CYP2C18-mediated metabolism was then developed on Template with the introduction of the idea of movement and fastening of ligands after Trigger-residue contact...
October 20, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38245949/exposure-response-analysis-of-the-efficacy-and-safety-of-esaxerenone-a-novel-nonsteroidal-mineralocorticoid-receptor-blocker-in-hypertensive-patients-with-or-without-diabetic-kidney-disease
#16
JOURNAL ARTICLE
Kazutaka Yoshihara, Masato Fukae, Helen Kastrissios, Russell Wada, Takako Shimizu
BACKGROUND: Esaxerenone is a novel non-steroidal mineralocorticoid receptor blocker. Here, we assessed efficacy and safety exposure-response relationships of esaxerenone and its covariates and thereby justified the recommended dosage regimens, focusing on the safety benefits of up-titration regimen in patients at higher risk for increased serum potassium (sK+ ). METHODS: The relationships between model-derived individual esaxerenone exposure and efficacy (blood pressure [BP]) and safety (increased sK+ ) were evaluated using multivariate linear regression and Cox regression analyses, respectively, using data from 1453 hypertensive patients with or without diabetic kidney disease in five clinical studies...
October 19, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38118335/food-effects-on-oral-drug-absorption-recent-advances-in-understanding-mechanisms-and-quantitative-prediction
#17
EDITORIAL
Yoshiyuki Shirasaka, Atsushi Kambayashi
No abstract text is available yet for this article.
October 16, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38064926/establishment-of-human-intestinal-organoids-derived-from-commercially-available-cryopreserved-intestinal-epithelium-and-evaluation-for-pharmacokinetic-study
#18
JOURNAL ARTICLE
Kentaro Okada, Jumpei Yokota, Tomoki Yamashita, Tatsuya Inui, Wataru Kishimoto, Hiroshi Nakase, Hiroyuki Mizuguchi
Human intestinal organoids (HIOs) have been reported to exert their functions in a way that mimics living organs, and HIOs-derived monolayers are expected to be applied to in vitro intestinal pharmacokinetic studies. However, HIOs are established from human tissue, which raises issues of availability and ethics. In the present study, to solve these problems, we have established intestinal organoids using commercially available cryopreserved human intestinal epithelial cells (C-IOs), and compared their functions with biopsy-derived human intestinal organoids (B-IOs) from a pharmacokinetic point of view...
October 8, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38064927/quantitative-prediction-of-transporter-mediated-drug-drug-interactions-using-the-mechanistic-static-pharmacokinetic-mspk-model
#19
JOURNAL ARTICLE
Satoshi Asano, Chie Kurosaki, Yuko Mori, Ryota Shigemi
Guidance/guidelines on drug-drug interactions (DDIs) have been issued in Japan, the United States, and Europe. These guidance/guidelines provide decision trees for conducting metabolizing enzyme-mediated clinical DDI studies; however, the decision trees for transporter-mediated DDIs lack quantitative prediction methods. In this study, the accuracy of a net-effect mechanistic static pharmacokinetics (MSPK) model containing the fraction transported (ft ) of transporters was examined to predict transporter-mediated DDIs...
October 7, 2023: Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/37924723/quantitation-and-characterization-of-glucosylsphingosine-in-cerebrospinal-fluid-csf-plasma-and-brain-of-monkey-model-with-gaucher-disease
#20
JOURNAL ARTICLE
Sho Sato, Shin-Ichi Matsumoto, Yohei Kosugi
Treatment with conduritol-β-epoxide (CBE) in preclinical species is expected to be a powerful approach to generate animal models of Gaucher disease (GD) and Parkinson's disease associated with heterozygous mutations in Glucocerebrosidase (GBA-PD). However, it is not fully elucidated how quantitatively the change in glucosylsphingosine (GlcSph) levels in cerebrospinal fluid (CSF) correlates with that in the brain, which is expected to be clinically informative. Herein, we aimed to investigate the correlation with successfully quantified GlcSph in monkey CSF by developing highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods...
September 15, 2023: Drug Metabolism and Pharmacokinetics
journal
journal
40362
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.